Fujita Kazutoshi, Ewing Charles M, Chan David Y S, Mangold Leslie A, Partin Alan W, Isaacs William B, Pavlovich Christian P
Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA.
Int J Cancer. 2009 Feb 1;124(3):664-9. doi: 10.1002/ijc.24007.
We have previously shown that endoglin (CD105) is upregulated in prostatic fluid of men with large volume prostate cancer. We chose to assess endoglin levels in urine and serum from men with prostate cancer or at increased risk for the disease: Urine samples were collected after digital rectal examination (DRE) from 99 men whose cancer status was confirmed by biopsy, and serum samples were collected from 20 men without prostate cancer at low risk for the disease and from 69 men diagnosed with prostate cancer that subsequently underwent radical prostatectomy (30 pT2, 39 pT3). Endoglin levels were assessed by ELISA. Urinary endoglin was elevated in men with biopsy-positive prostate cancer compared to biopsy-negative men (p=0.0014). Urinary endoglin levels in men with prostate cancer correlated with radical prostatectomy tumor volume. The area under the receiver operating characteristic (ROC) curve was 0.72 for urinary endoglin and 0.50 for serum prostate-specific antigen (PSA; sensitivity for cancer detection 73%, specificity 63%). There were no differences in serum endoglin between normal and cancer cases, but there were increases in serum endoglin in non-organ confined (NOC, pT3+) versus organ-confined (OC, pT2) cases (p=0.0004). The area under the ROC curve was 0.75 for serum endoglin and 0.63 for PSA for predicting NOC status, with a sensitivity of 67% and a specificity of 80%. In conclusion, elevations in post-DRE urinary endoglin suggest there may be value in further studying endoglin as a urinary biomarker of prostate cancer. Endoglin levels in both urine and serum may aid in prostate cancer detection and prognostication.
我们之前已经表明，在患有大体积前列腺癌的男性前列腺液中，内皮糖蛋白（CD105）上调。我们选择评估前列腺癌患者或该疾病风险增加的男性尿液和血清中的内皮糖蛋白水平：在直肠指检（DRE）后，从99名经活检确诊癌症状态的男性中收集尿液样本，从20名患该疾病低风险的非前列腺癌男性以及69名随后接受根治性前列腺切除术的前列腺癌男性（30例pT2，39例pT3）中收集血清样本。通过酶联免疫吸附测定（ELISA）评估内皮糖蛋白水平。与活检阴性的男性相比，活检阳性的前列腺癌男性尿液中的内皮糖蛋白升高（p = 0.0014）。前列腺癌男性的尿液内皮糖蛋白水平与根治性前列腺切除术的肿瘤体积相关。尿内皮糖蛋白的受试者工作特征（ROC）曲线下面积为0.72，血清前列腺特异性抗原（PSA）为0.50（癌症检测灵敏度73％，特异性63％）。正常和癌症病例之间血清内皮糖蛋白无差异，但非器官局限性（NOC，pT3 +）与器官局限性（OC，pT2）病例相比血清内皮糖蛋白增加（p = 0.0004）。血清内皮糖蛋白预测NOC状态的ROC曲线下面积为0.75，PSA为0.63，灵敏度为67％，特异性为80％。总之，DRE后尿内皮糖蛋白升高表明进一步研究内皮糖蛋白作为前列腺癌尿液生物标志物可能有价值。尿液和血清中的内皮糖蛋白水平可能有助于前列腺癌的检测和预后判断。
